Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH.
Anagnostis P, Rizos CV, Skoumas I, Rallidis L, Tziomalos K, Skalidis E, Kotsis V, Doumas M, Kolovou G, Sfikas G, Bilianou E, Koutagiar I, Agapakis D, Zacharis E, Antza C, Koumaras C, Boutari C, Liamis G, Liberopoulos EN. Anagnostis P, et al. Among authors: zacharis e. Curr Pharm Des. 2021;27(21):2537-2544. doi: 10.2174/1381612827666210216151645. Curr Pharm Des. 2021. PMID: 33593250
A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study.
Alexopoulos D, Anastasiou-Nana M, Elisaf MS, Liberopoulos E, Rallidis LS, Davos CH, Moulis A, Nikas N, Zacharis E, Vardas P; CHALLENGE Investigators. Alexopoulos D, et al. Among authors: zacharis e. Int J Cardiol. 2016 Aug 15;217:183-9. doi: 10.1016/j.ijcard.2016.05.003. Epub 2016 May 3. Int J Cardiol. 2016. PMID: 27183455
Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G, Diakoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, Liberopoulos EN, Matsouka F, Tsoutsinos A, Mastorakou I, Katsikas T, Mavrogeni S, Hatzigeorgiou G. Kolovou G, et al. Among authors: zacharis e. Eur J Prev Cardiol. 2020 Jan;27(2):157-165. doi: 10.1177/2047487319870007. Epub 2019 Aug 12. Eur J Prev Cardiol. 2020. PMID: 31403880
Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake.
Vlachopoulos C, Koutagiar I, Skoumas I, Terentes-Printzios D, Zacharis E, Kolovou G, Stamatelopoulos K, Rallidis L, Katsiki N, Bilianou H, Liberopoulos E, Miliou A, Kafouris P, Georgakopoulos A, Gardikioti V, Tousoulis D, Anagnostopoulos CD. Vlachopoulos C, et al. Among authors: zacharis e. JACC Cardiovasc Imaging. 2019 Dec;12(12):2573-2574. doi: 10.1016/j.jcmg.2019.09.024. JACC Cardiovasc Imaging. 2019. PMID: 31806185 Free article. No abstract available.
Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.
Rizos CV, Florentin M, Skoumas I, Tziomalos K, Rallidis L, Kotsis V, Athyros V, Skalidis E, Kolovou G, Garoufi A, Bilianou E, Koutagiar I, Agapakis D, Kiouri E, Antza C, Katsiki N, Zacharis E, Attilakos A, Sfikas G, Anagnostis P, Panagiotakos DB, Liberopoulos EN. Rizos CV, et al. Among authors: zacharis e. Lipids Health Dis. 2020 May 28;19(1):114. doi: 10.1186/s12944-020-01289-5. Lipids Health Dis. 2020. PMID: 32466791 Free PMC article.
LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV, Skoumas I, Rallidis L, Skalidis E, Tziomalos K, Garoufi A, Anagnostis P, Sfikas G, Kotsis V, Doumas M, Kolovou G, Lambadiari V, Dima I, Kiouri E, Zacharis E, Agapakis D, Attilakos A, Antza C, Vlachopoulos C, Liberopoulos EN. Rizos CV, et al. Among authors: zacharis e. Int J Cardiol. 2021 Dec 15;345:119-124. doi: 10.1016/j.ijcard.2021.10.024. Epub 2021 Oct 21. Int J Cardiol. 2021. PMID: 34687802
59 results